Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered embryo scoring could boost IVF success

NCT ID NCT05483985

Knowledge-focused Sponsor: Alife Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a device called the Alife Hera System, which uses a computer algorithm to score embryos based on images and patient information. The goal was to see if using this score alongside standard methods helps doctors choose the embryo most likely to result in a pregnancy. The study involved 444 women undergoing IVF, and compared pregnancy rates when the device was used versus standard selection alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Alife Hera System (a software algorithm that analyzes embryo images to predict pregnancy)
What this could lead to
If successful, this device could help IVF doctors choose the embryo most likely to lead to a pregnancy, potentially improving success rates.
What could go wrong
This is a completed study, but the device is only an aid—it may not significantly improve pregnancy rates over standard methods. Results are not yet widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

444 people

The number who actually took part.

Started

Jul 2022

Finished

Dec 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 43 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. \>21 and \< 43 years of age 2. Women undergoing in vitro fertilization treatment using their own eggs 3. At least 8 eggs retrieved 4. Fertilization using only ejaculated sperm including donor sperm (fresh or frozen) 5. Single embryo transfer (SET) 6. Willing to comply with study protocol and procedures and be able to speak English 7. Willing to provide written informed consent Exclusion Criteria: 1. Gestational carriers 2. Use of re-inseminated eggs 3. Use of donor eggs 4. History of cancer 5. Fertilization using surgically removed sperm 6. Transfer of multiple (more than one) embryos at once 7. Participants undergoing IVF with intent to bank embryos (i.e. no intention of embryo transfer for at least 6 months following egg retrieval) 8. Concurrent participation in another clinical study that might interfere with the study results in either study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infertility are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infertility

Contacts and locations

Locations

  • Aspire Fertility

    San Antonio, Texas, 78258, United States

  • CCRM

    Menlo Park, California, 94025, United States

  • Center for Reproductive Medicine

    Winter Park, Florida, 32789, United States

  • IVF Florida Reproductive Associates

    Margate, Florida, 33063, United States

  • Ovation Fertility

    Austin, Texas, 78731, United States

  • Reproductive Care Center

    Sandy City, Utah, 84092, United States

  • Reproductive Science Center

    San Ramon, California, 94583, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.